Mutation profile and prognostic relevance in elderly patients with de novo acute myeloid leukemia treated with decitabine‐based chemotherapy

Co-occurrence of DNMT3A, NPM1, FLT3 mutations identifies a subset of acute myeloid leukemia with adverse prognosis

(2020) Matheus F Bezerra et al.   BLOOD

Importance of prognostic stratification via gene mutation analysis in elderly patients with acute myelogenous leukemia

(2019) Yusuke Fujiwara et al.   International Journal of Laboratory Hematology

Epigenetic modifier gene mutations‐positive AML patients with intermediate‐risk karyotypes benefit from decitabine with CAG regimen

(2019) Qingyu Xu et al.   INTERNATIONAL JOURNAL OF CANCER

Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology

(2019) Martin S. Tallman et al.   Journal of the National Comprehensive Cancer Network

Mutation profile and associated clinical features in Chinese patients with cytogenetically normal acute myeloid leukemia

(2018) S. Wang et al.   International Journal of Laboratory Hematology

Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies

(2018) Ann-Kathrin Eisfeld et al.   LEUKEMIA

Decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin is as effective as standard dose chemotherapy in the induction treatment for patients aged from 55 to 69 years old with newly diagnosed acute myeloid leukemia

(2018) Jiayu Huang et al.   LEUKEMIA & LYMPHOMA

Midostaurin added to chemotherapy and continued single agent maintenance therapy in acute myeloid leukemia with FLT3-ITD

(2018) Richard F. Schlenk et al.   BLOOD

Next-generation sequencing-based genetic landscape and its clinical implications for Chinese acute myeloid leukemia patients

(2018) Xin-xin Cao et al.   Cancer Cell International

Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care

(2018) Hartmut Döhner et al.   LEUKEMIA

Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial

(2018) Nicholas J Short et al.   Lancet Haematology

Genomics of Acute Myeloid Leukemia Diagnosis and Pathways

(2017) Lars Bullinger et al.   JOURNAL OF CLINICAL ONCOLOGY

Emerging therapies for acute myeloid leukemia

(2017) Caner Saygin et al.   Journal of Hematology & Oncology

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

(2016) Hartmut Döhner et al.   BLOOD

Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia

(2016) K. H. Metzeler et al.   BLOOD

Genetic alterations and their clinical implications in older patients with acute myeloid leukemia

(2016) C-H Tsai et al.   LEUKEMIA

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes

(2016) John S. Welch et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genomic Classification and Prognosis in Acute Myeloid Leukemia

(2016) Elli Papaemmanuil et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance

(2015) D. Grimwade et al.   BLOOD

Acute Myeloid Leukemia

(2015) Hartmut Döhner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia

(2015) Jianyong Li et al.   Oncotarget

Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients

(2014) R Kihara et al.   LEUKEMIA

Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1 and TET2 mutations

(2014) Robert S Ohgami et al.   MODERN PATHOLOGY

Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes

(2014) Siddhartha Jaiswal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

(2012) Hagop M. Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome

(2012) S Schnittger et al.   LEUKEMIA

Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value

(2011) M. Pratcorona et al.   HAEMATOLOGICA

Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations

(2010) W.-C. Chou et al.   BLOOD

Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia

(2010) Farhad Ravandi et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid Leukemia

(2009) Amanda F. Cashen et al.   JOURNAL OF CLINICAL ONCOLOGY